Diagnosis, Differential ; Humans ; Molecular Biology ; Vascular Malformations/genetics*

OBJECTIVETo detect the expression of TRAIL protein and mRNA in hemangiomas and vascular malformations.

METHODSSections of 33 proliferative hemangiomas,28 involuting hemangiomas and 29 vascular malformations were immunostained for TRAIL protein, TRAIL mRNA was examined by in situ hybridization in these tissue.

RESULTSThe TRAIL protein positive rates in proliferative hemangiomas, involuting hemangiomas, vascular malformations and normal skins were respectively 45.45% (15/33), 78.57% (22/28), 0% and 0%. There were significant differences among the four pathologies (P < 0.01). The difference between proliferative hemangiomas and involuting hemangiomas was also significant (P < 0.01). The TRAIL mRNA positive rates were 66.67% (11/33), 89.29 (25/28), 0% and 0% respectively. There were also significant differences among the four pathologies (P < 0.01). The difference between proliferative hemangiomas and involuting hemangiomas was also significant (P < 0.01).

CONCLUSIONSTRAIL could induce endothelial apoptosis and cause regression of hemangiomas.

Apoptosis ; Female ; Hemangioma ; metabolism ; pathology ; Humans ; In Situ Hybridization ; Infant, Newborn ; Male ; Microcirculation ; RNA, Messenger ; genetics ; TNF-Related Apoptosis-Inducing Ligand ; genetics ; metabolism ; Vascular Malformations ; metabolism ; pathology